|
Gene: POLDIP2 |
Gene summary for POLDIP2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | POLDIP2 | Gene ID | 26073 |
Gene name | DNA polymerase delta interacting protein 2 | |
Gene Alias | PDIP38 | |
Cytomap | 17q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | B4DEM9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26073 | POLDIP2 | GSM4909286 | Human | Breast | IDC | 2.35e-04 | 1.50e-01 | 0.1081 |
26073 | POLDIP2 | GSM4909294 | Human | Breast | IDC | 1.72e-02 | 2.35e-01 | 0.2022 |
26073 | POLDIP2 | GSM4909311 | Human | Breast | IDC | 3.14e-09 | -8.46e-02 | 0.1534 |
26073 | POLDIP2 | GSM4909312 | Human | Breast | IDC | 1.02e-04 | 4.98e-02 | 0.1552 |
26073 | POLDIP2 | GSM4909319 | Human | Breast | IDC | 2.84e-20 | 8.76e-02 | 0.1563 |
26073 | POLDIP2 | GSM4909321 | Human | Breast | IDC | 1.84e-03 | 4.08e-02 | 0.1559 |
26073 | POLDIP2 | brca1 | Human | Breast | Precancer | 1.16e-03 | 1.95e-01 | -0.0338 |
26073 | POLDIP2 | brca2 | Human | Breast | Precancer | 4.46e-04 | 2.03e-01 | -0.024 |
26073 | POLDIP2 | NCCBC2 | Human | Breast | DCIS | 3.70e-07 | 5.42e-01 | 0.1554 |
26073 | POLDIP2 | NCCBC5 | Human | Breast | DCIS | 2.15e-07 | 2.88e-01 | 0.2046 |
26073 | POLDIP2 | P1 | Human | Breast | IDC | 2.63e-02 | -2.86e-02 | 0.1527 |
26073 | POLDIP2 | DCIS2 | Human | Breast | DCIS | 5.37e-28 | 4.47e-02 | 0.0085 |
26073 | POLDIP2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.02e-05 | 1.34e-01 | 0.0155 |
26073 | POLDIP2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 9.80e-06 | 2.90e-01 | -0.1808 |
26073 | POLDIP2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.08e-04 | 3.48e-01 | -0.0811 |
26073 | POLDIP2 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.05e-02 | 1.75e-01 | -0.1088 |
26073 | POLDIP2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.72e-11 | 3.72e-01 | -0.1954 |
26073 | POLDIP2 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.69e-04 | 5.57e-01 | -0.2602 |
26073 | POLDIP2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.06e-03 | 2.66e-01 | -0.1207 |
26073 | POLDIP2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.15e-08 | 3.04e-01 | -0.1464 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004578520 | Oral cavity | OSCC | positive regulation of cell adhesion | 225/7305 | 437/18723 | 6.06e-08 | 1.09e-06 | 225 |
GO:00903076 | Oral cavity | OSCC | mitotic spindle assembly | 46/7305 | 65/18723 | 2.06e-07 | 3.29e-06 | 46 |
GO:00512255 | Oral cavity | OSCC | spindle assembly | 73/7305 | 117/18723 | 2.51e-07 | 3.96e-06 | 73 |
GO:000195215 | Oral cavity | OSCC | regulation of cell-matrix adhesion | 78/7305 | 128/18723 | 4.05e-07 | 6.02e-06 | 78 |
GO:000716016 | Oral cavity | OSCC | cell-matrix adhesion | 125/7305 | 233/18723 | 3.76e-06 | 4.45e-05 | 125 |
GO:000091010 | Oral cavity | OSCC | cytokinesis | 97/7305 | 173/18723 | 3.82e-06 | 4.51e-05 | 97 |
GO:003209210 | Oral cavity | OSCC | positive regulation of protein binding | 54/7305 | 85/18723 | 4.05e-06 | 4.71e-05 | 54 |
GO:00900688 | Oral cavity | OSCC | positive regulation of cell cycle process | 126/7305 | 236/18723 | 4.75e-06 | 5.44e-05 | 126 |
GO:005189316 | Oral cavity | OSCC | regulation of focal adhesion assembly | 43/7305 | 66/18723 | 1.52e-05 | 1.52e-04 | 43 |
GO:009010916 | Oral cavity | OSCC | regulation of cell-substrate junction assembly | 43/7305 | 66/18723 | 1.52e-05 | 1.52e-04 | 43 |
GO:00616405 | Oral cavity | OSCC | cytoskeleton-dependent cytokinesis | 60/7305 | 100/18723 | 1.69e-05 | 1.67e-04 | 60 |
GO:001081120 | Oral cavity | OSCC | positive regulation of cell-substrate adhesion | 71/7305 | 123/18723 | 1.96e-05 | 1.87e-04 | 71 |
GO:015011617 | Oral cavity | OSCC | regulation of cell-substrate junction organization | 45/7305 | 71/18723 | 2.76e-05 | 2.56e-04 | 45 |
GO:00105075 | Oral cavity | OSCC | negative regulation of autophagy | 51/7305 | 85/18723 | 7.08e-05 | 5.62e-04 | 51 |
GO:000195416 | Oral cavity | OSCC | positive regulation of cell-matrix adhesion | 37/7305 | 58/18723 | 1.15e-04 | 8.35e-04 | 37 |
GO:00162421 | Oral cavity | OSCC | negative regulation of macroautophagy | 23/7305 | 34/18723 | 6.77e-04 | 3.78e-03 | 23 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
GO:00705847 | Oral cavity | OSCC | mitochondrion morphogenesis | 15/7305 | 21/18723 | 2.65e-03 | 1.16e-02 | 15 |
GO:00063011 | Oral cavity | OSCC | postreplication repair | 20/7305 | 31/18723 | 3.57e-03 | 1.49e-02 | 20 |
GO:00513024 | Oral cavity | OSCC | regulation of cell division | 87/7305 | 177/18723 | 3.75e-03 | 1.55e-02 | 87 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
POLDIP2 | SNV | Missense_Mutation | novel | c.326C>A | p.Ser109Tyr | p.S109Y | Q9Y2S7 | protein_coding | tolerated(0.23) | benign(0.112) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
POLDIP2 | SNV | Missense_Mutation | novel | c.596N>T | p.Arg199Ile | p.R199I | Q9Y2S7 | protein_coding | deleterious(0) | benign(0.306) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
POLDIP2 | SNV | Missense_Mutation | novel | c.359N>A | p.Gly120Asp | p.G120D | Q9Y2S7 | protein_coding | tolerated(0.31) | benign(0.035) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
POLDIP2 | SNV | Missense_Mutation | novel | c.1013N>T | p.Arg338Ile | p.R338I | Q9Y2S7 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POLDIP2 | SNV | Missense_Mutation | novel | c.601N>A | p.Leu201Ile | p.L201I | Q9Y2S7 | protein_coding | deleterious(0.04) | probably_damaging(0.934) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
POLDIP2 | SNV | Missense_Mutation | novel | c.262N>G | p.Phe88Val | p.F88V | Q9Y2S7 | protein_coding | deleterious(0) | possibly_damaging(0.521) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POLDIP2 | SNV | Missense_Mutation | rs782542378 | c.844N>T | p.Arg282Trp | p.R282W | Q9Y2S7 | protein_coding | deleterious(0.01) | probably_damaging(0.913) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
POLDIP2 | SNV | Missense_Mutation | novel | c.455N>T | p.Thr152Ile | p.T152I | Q9Y2S7 | protein_coding | deleterious(0.01) | benign(0.084) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
POLDIP2 | SNV | Missense_Mutation | novel | c.1033G>C | p.Asp345His | p.D345H | Q9Y2S7 | protein_coding | deleterious(0) | possibly_damaging(0.718) | TCGA-B5-A11R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
POLDIP2 | SNV | Missense_Mutation | novel | c.1057C>A | p.Leu353Met | p.L353M | Q9Y2S7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |